EUVIMEDSkopri EUVIMED
Vergleichsstudie

Comparative Binding Dynamics of Minibinder 8.6 and HBD3 With TLR3 as Adjuvants for Developing a Peptide‐Based Multi‐Epitope Subunit Vaccine Against mCRPC : A Molecular Dynamics Study

Ishani Paul iD, Soumyadeep Ray, Muskan Tewari, Mowmita Saha iD, Sujay Ray iD

Proteins: Structure, Function, and Bioinformatics · 2026

DOI: 10.1002/prot.70124 ↗

At a glance

Vergleichsstudie in Proteins: Structure, Function, and Bioinformatics, 2026. Written by Ishani Paul and 4 co-authors. Institution: Amity Institute of Biotechnology, Amity University, Kolkata, India. Major MEDLINE topics: Adjuvants, Immunologic, beta-Defensins, Cancer Vaccines, Epitopes. 73 references.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Metastatic castration resistance prostate cancer (mCRPC) is the advanced state of prostate cancer where majority of patients succumb to ineffective treatment perspectives like androgen deprivation alongside salvage therapies. mCRPC is predominantly orchestrated by androgen receptor (AR)‐dependent gene expression. On the account of AR being a “potentially attractive immunological target”, an immunoinformatics pipeline was built to identify and screen mutation‐independent, broad MHC covering, potential antigenic, non‐allergenic, non‐toxic and soluble epitopes. The filtered epitopes required assembly into a unified construct with interconnecting linkers and adjuvant and further TLR3‐docking. We chose TLR3 because of its pro‐apoptotic activity in prostate cancer, to check active immune response by the vaccine. Our study was not confined to the use of a conventional adjuvant like human beta defensin‐3 but it extended to the scope of utilization of a protein‐based TLR3‐specific agonist as an adjuvant for assembling the second composite construct. Our path was guided by the discovery of TLR3‐specific agonist minibinder 8.6 (a small, hyperstable protein) by Adams et al. An extensively comparative molecular dynamics study of the free state and bound states of the two constructs unveiled a more stable interaction, complex stability and immune response attributing to the specificity of the minibinder‐based construct towards TLR3. Our work circumscribes a multi‐headed approach beginning with peptide subunit multi‐epitope vaccine construct design for mitigating mCRPC; secondarily, endorsing the advocacy of TLR3‐agonizing minibinders as vaccine adjuvants for enhanced immunity and finally posing a comparative framework of minibinder 8.6 over HBD3, as a more potential adjuvant, apprehending wet‐lab proof.

Subjects

MeSH terms (MEDLINE)

Adjuvants, Immunologicbeta-DefensinsCancer VaccinesEpitopesImmunoinformaticsProtein Subunit VaccinesToll-Like Receptor 3HumansMaleMolecular Docking SimulationMolecular Dynamics SimulationProtein BindingToll-Like Receptor Agonists

Substances

Adjuvants, Immunologicbeta-DefensinsCancer VaccinesDEFB103A protein, humanEpitopesProtein Subunit VaccinesTLR3 protein, humanToll-Like Receptor 3Toll-Like Receptor Agonists

Authors and institutions

  • Amity Institute of Biotechnology, Amity University, Kolkata, India.
  • Department of Zoology, Seth Anandram Jaipuria College, Kolkata, India.

ORCID profiles: Ishani Paul, Mowmita Saha, Sujay Ray

Cite

APA

Paul, I., Ray, S., Tewari, M., Saha, M., & Ray, S. (2026). Comparative Binding Dynamics of Minibinder 8.6 and HBD3 With TLR3 as Adjuvants for Developing a Peptide‐Based Multi‐Epitope Subunit Vaccine Against mCRPC : A Molecular Dynamics Study. Proteins: Structure, Function, and Bioinformatics. https://doi.org/10.1002/prot.70124

Vancouver

Paul I, Ray S, Tewari M, Saha M, Ray S. Comparative Binding Dynamics of Minibinder 8.6 and HBD3 With TLR3 as Adjuvants for Developing a Peptide‐Based Multi‐Epitope Subunit Vaccine Against mCRPC : A Molecular Dynamics Study. Proteins: Structure, Function, and Bioinformatics. 2026. doi:10.1002/prot.70124

BibTeX
@article{Paul2026,
  author = {Paul, Ishani and Ray, Soumyadeep and Tewari, Muskan and Saha, Mowmita and Ray, Sujay},
  title = {Comparative Binding Dynamics of Minibinder 8.6 and HBD3 With TLR3 as Adjuvants for Developing a Peptide‐Based Multi‐Epitope Subunit Vaccine Against mCRPC : A Molecular Dynamics Study},
  journal = {Proteins: Structure, Function, and Bioinformatics},
  year = {2026},
  doi = {10.1002/prot.70124}
}
Start for free →